What Is Retatrutide?
Retatrutide (research designation LY3437943) is a synthetic peptide described in peer-reviewed literature as an agonist at the GIP, GLP-1 and glucagon receptors. It is an investigational compound studied under regulated clinical trial conditions and is supplied here only as a laboratory reference material.
Published 2026-08-22 · Updated 2026-08-22 · Reviewed by the Lana editorial team
Molecular information
CAS 2381089-83-2; molecular weight approximately 4731 g/mol; synonym LY3437943.
What mechanisms have been investigated?
Published pharmacology describes triple incretin receptor agonism. Clinical investigation of retatrutide is conducted by its developer under trial protocols; nothing in that research applies to reference material supplied for laboratory work.
Regulatory and research status
Investigational. Not approved by Health Canada or the FDA. Supplied for in-vitro laboratory research only.